Holen Sie sich die Stockscreener-App
2.61
4.82%
0.12
Schlusskurs vom Vortag:
$2.49
Offen:
$2.5
24-Stunden-Volumen:
217.61K
Relative Volume:
0.90
Marktkapitalisierung:
$116.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-27.66M
KGV:
-2.7474
EPS:
-0.95
Netto-Cashflow:
$-24.36M
1W Leistung:
+9.21%
1M Leistung:
-4.74%
6M Leistung:
-18.44%
1J Leistung:
-52.20%
1-Tages-Spanne:
$2.485
$2.69
1-Wochen-Bereich:
$2.3149
$2.69
52-Wochen-Spanne:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
Firmenname
Genelux Corp
Sektor
Branche
Telefon
805-267-9889
Adresse
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.61 | 111.35M | 0 | -27.66M | -24.36M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-21 | Eingeleitet | Lake Street | Buy |
| 2024-10-29 | Eingeleitet | Guggenheim | Buy |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-11-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-09-12 | Eingeleitet | Maxim Group | Buy |
| 2023-02-15 | Eingeleitet | The Benchmark Company | Speculative Buy |
Alle ansehen
Genelux Corp Aktie (GNLX) Neueste Nachrichten
Will Genelux Corporation stock continue dividend increasesJuly 2025 PreEarnings & Weekly Stock Breakout Alerts - mfd.ru
Genelux Updates Corporate Presentation for Investors and Stakeholders - The Globe and Mail
US Stocks Recap: Is Outlook Therapeutics Inc stock good for income investorsM&A Rumor & Safe Capital Growth Plans - baoquankhu1.vn
Genelux appoints Jason Litten as CMO - MSN
Brokers Offer Predictions for Genelux Q1 Earnings - Defense World
Aug Sectors: Will Genelux Corporation benefit from AI trendsExit Point & High Yield Stock Recommendations - baoquankhu1.vn
Aug Momentum: Will Genelux Corporation benefit from AI trendsRate Hike & Smart Money Movement Tracker - baoquankhu1.vn
Biotech Genelux to stream CEO and team in live Titan Partners fireside chat - Stock Titan
Genelux Announces Underwritten Public Offering to Raise Capital - The Globe and Mail
Can Genelux Corporation stock sustain revenue growth2025 Earnings Surprises & AI Powered Trade Plan Recommendations - Улправда
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Genelux Corporation announces pricing of $20.0 million underwritten public offering of common stock - MarketScreener
Genelux prices public offering of 6.67 million shares at $3 each - Investing.com Australia
Genelux prices public offering of 6.67 million shares at $3 each By Investing.com - Investing.com South Africa
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock | GNLX Stock News - Quiver Quantitative
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Genelux stock falls after announcing proposed public offering By Investing.com - Investing.com Australia
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Genelux data update indicates disease early control, says H.C. Wainwright - MSN
Multiple Insiders Sold Genelux Shares Presenting Weak Signs For Investors - simplywall.st
Genelux reports interim data of systemic administration of Olvi-Vec - TipRanks
After-Hours Biotech Rally: Alumis, Genelux, Bright Minds, Context Therapeutics Post Big Gains - Nasdaq
Genelux reports encouraging interim data for Olvi-Vec trials - MSN
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data By Investing.com - Investing.com South Africa
Genelux stock maintains Buy rating at H.C. Wainwright on promising cancer trial data - Investing.com Canada
Maintaining Buy on Genelux: Early Olvi-Vec Data Signal Differentiated Potential in Relapsed/Refractory Lung Cancer - TipRanks
Genelux Reports Encouraging Interim Data for Olvi-Vec Trials - TipRanks
Experimental treatment shrank lung tumors up to 85% in early trial - Stock Titan
Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer - Sahm
Genelux Appoints Veteran Oncologist Jason Litten as CMO - The Globe and Mail
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Genelux appoints Jason Litten as chief medical officer By Investing.com - Investing.com Nigeria
Genelux Corporation Announces Change of Chief Medical Officer - marketscreener.com
Genelux appoints Jason Litten as chief medical officer - Investing.com India
Genelux Corporation Appoints Dr. Jason Litten as Chief Medical Officer to Advance Olvi-Vec Development - Quiver Quantitative
GENELUX CORP : BENCHMARK CUTS TARGET PRICE TO $23 FROM $25 - 富途牛牛
How interest rate cuts could boost Genelux Corporation stockAnalyst Upgrades & AI Alerts You Can Actually Trust - Bollywood Helpline
Flputnam Investment Management Co. Raises Holdings in Genelux Corporation $GNLX - MarketBeat
Genelux (NASDAQ:GNLX) Cut to Sell at Wall Street Zen - Defense World
Cappello, Genelux CTO, sells $14k in GNLX stock By Investing.com - Investing.com Nigeria
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 4,509 Shares - MarketBeat
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 12,673 Shares of Stock - MarketBeat
Finanzdaten der Genelux Corp-Aktie (GNLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Genelux Corp-Aktie (GNLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Yu Yong | SVP, Clinical Development |
Nov 17 '25 |
Sale |
5.37 |
973 |
5,224 |
145,844 |
| Zindrick Thomas | President and CEO |
Aug 21 '25 |
Sale |
3.33 |
12,673 |
42,159 |
542,940 |
| Zindrick Thomas | President and CEO |
Nov 17 '25 |
Sale |
5.37 |
4,509 |
24,211 |
538,431 |
| Cappello Joseph | Chief Technical Officer |
Aug 21 '25 |
Sale |
3.34 |
2,733 |
9,137 |
157,033 |
| Cappello Joseph | Chief Technical Officer |
Nov 17 '25 |
Sale |
5.37 |
973 |
5,224 |
156,060 |
| Smalling Ralph | Head of Regulatory |
Aug 21 '25 |
Sale |
3.36 |
1,244 |
4,177 |
69,746 |
| Smalling Ralph | Head of Regulatory |
Sep 03 '25 |
Sale |
3.36 |
580 |
1,948 |
69,166 |
| Smalling Ralph | Head of Regulatory |
Nov 17 '25 |
Sale |
5.37 |
343 |
1,842 |
68,823 |
| Smalling Ralph | Head of Regulatory |
Dec 05 '25 |
Sale |
4.69 |
165 |
774 |
68,658 |
| Thomas John | Director |
Dec 01 '25 |
Sale |
5.00 |
10,000 |
50,008 |
492,784 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):